That portion of the electromagnetic spectrum usually sensed as heat. Infrared wavelengths are longer than those of visible light, extending into the microwave frequencies. They are used therapeutically as heat, and also to warm food in restaurants.
An optical source that emits photons in a coherent beam. Light Amplification by Stimulated Emission of Radiation (LASER) is brought about using devices that transform light of varying frequencies into a single intense, nearly nondivergent beam of monochromatic radiation. Lasers operate in the infrared, visible, ultraviolet, or X-ray regions of the spectrum.
Discrete concentrations of energy, apparently massless elementary particles, that move at the speed of light. They are the unit or quantum of electromagnetic radiation. Photons are emitted when electrons move from one energy state to another. (From Hawley's Condensed Chemical Dictionary, 11th ed)
Treatment using irradiation with LASER light of low power intensity so that the effects are not due to heat, as they are in LASER THERAPY.
Lasers with a semiconductor diode as the active medium. Diode lasers transform electric energy to light using the same principle as a light-emitting diode (LED), but with internal reflection capability, thus forming a resonator where a stimulated light can reflect back and forth, allowing only a certain wavelength to be emitted. The emission of a given device is determined by the active compound used (e.g., gallium arsenide crystals doped with aluminum or indium). Typical wavelengths are 810, 1,060 and 1,300 nm. (From UMDNS, 2005)
The use of photothermal effects of LASERS to coagulate, incise, vaporize, resect, dissect, or resurface tissue.
Exclusive legal rights or privileges applied to inventions, plants, etc.
Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.
A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere.
Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)
The rate dynamics in chemical or physical systems.
An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.
Persons who are enrolled in research studies or who are otherwise the subjects of research.
Research that involves the application of the natural sciences, especially biology and physiology, to medicine.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
The minute vessels that connect the arterioles and venules.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
Cell surface proteins that bind erythropoietin with high affinity and trigger intracellular changes influencing the behavior of cells.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
The lipid-rich sheath surrounding AXONS in both the CENTRAL NERVOUS SYSTEMS and PERIPHERAL NERVOUS SYSTEM. The myelin sheath is an electrical insulator and allows faster and more energetically efficient conduction of impulses. The sheath is formed by the cell membranes of glial cells (SCHWANN CELLS in the peripheral and OLIGODENDROGLIA in the central nervous system). Deterioration of the sheath in DEMYELINATING DISEASES is a serious clinical problem.
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
Recurrent conditions characterized by epileptic seizures which arise diffusely and simultaneously from both hemispheres of the brain. Classification is generally based upon motor manifestations of the seizure (e.g., convulsive, nonconvulsive, akinetic, atonic, etc.) or etiology (e.g., idiopathic, cryptogenic, and symptomatic). (From Mayo Clin Proc, 1996 Apr;71(4):405-14)
A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the temporal lobe, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic (i.e., related to an identified disease process or lesion). (From Adams et al., Principles of Neurology, 6th ed, p321)
The organ of sight constituting a pair of globular organs made up of a three-layered roughly spherical structure specialized for receiving and responding to light.
A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic (i.e., occurring secondary to known disease processes such as infections, hypoxic-ischemic injuries, trauma, etc.).
Phase I taught at intermediate and senior levels; Phase II; single-phase programs offered at select institutions; and General/ ... Multiple aspects of Joint Professional Military Education are encompassed in the term; curricula, standards and education ... Successful completion of both Phase I and Phase II of the JPME are among the qualifications for the designation Joint Staff ... while the National War College and the Industrial College of the Armed Forces were entitled to offer both Phase I and Phase II ...
CVPR.CS1 maint: multiple names: authors list (link) Mohit Gupta; Shree K. Nayar (2012). "Micro Phase Shifting". Proc. CVPR. " ... Stripe frequency and phase deliver similar cues and can be analyzed by a Fourier transform. Finally, the wavelet transform has ... Therefore, the phase shift method has been widely established: A number of at least 3, typically about 10 exposures are taken ... By phase shifting, surface detail of e.g. 1/10 the stripe pitch can be resolved. Current optical stripe pattern profilometry ...
The crystal form has been described as anti-NiAs structure and is known as the β-phase. Also known as ε-CrH, the space group is ... doi:10.1016/0025-5408(74)90037-3. ISSN 0025-5408.CS1 maint: multiple names: authors list (link) Venkatraman, M; J.P Neumann ( ... A face-centered cubic (fcc) phase of chromium hydride can also be produced when chromium is electrodeposited. Cloyd A. Snavely ... CS1 maint: discouraged parameter (link) Stock, Allen D.; Kenneth I. Hardcastle (1970). "Phase and composition analysis of ...
"Phase d'évaluation - Zinneke". zinneke.org.CS1 maint: multiple names: authors list (link) Website of the Zinneke Parade ...
VA Zaitsev, LD Krigman, LN Kogarko (2004). "Pseudobinare phase diagram lamprophyllite-nepheline". Lithos. EMPG-X special volume ... maint: multiple names: authors list (link) v t e. ...
Sydney Metro - a similar project in Sydney, Australia, with multiple stages and projects; first phase opened in 2019. "TfL Rail ... During this initial phase of operation, services are being operated by MTR under the TfL Rail brand. Following the practice ...
... "thick-phase grating" approximation, which has never been used, 7. Moodie's polynomial expression for multiple scattering, 8. ... The wave is then multiplied by a propagator, inverse Fourier Transformed, multiplied by a phase grating term yet again, and the ... In the case of the small-angle approximation ( θ ∼ {\displaystyle \theta \sim } 100 mRad) we can approximate the phase shift as ... In this paper, we will primarily focus on the multislice method for simulation of diffraction patterns, including multiple ...
Deng, Y.; Y. Huang, J. L. Jacobsen, J. Salas, and A. D. Sokal (2011). "Finite-temperature phase transition in a class of four- ... doi:10.1088/0305-4470/33/42/104.CS1 maint: multiple names: authors list (link) Lorenz, B; I. Orgzall and H.-O. Heuer (1993). " ... Bibcode:1961PhRv..123.1566V. doi:10.1103/PhysRev.123.1566.CS1 maint: multiple names: authors list (link) Gaunt, D. S.; M. F. ... doi:10.1016/S0921-4526(97)00985-X.CS1 maint: multiple names: authors list (link) Haji Akbari, Amir; R. M. Ziff (2009). " ...
doi:10.1016/0031-0182(81)90053-5. ISSN 0031-0182.CS1 maint: multiple names: authors list (link) Prevec, R., 2014. PHASE 1 ... doi:10.1016/S0899-5362(96)00048-6. ISSN 1464-343X.CS1 maint: multiple names: authors list (link) Johnson, M.R., Van Vuuren, C.J ... doi:10.1016/S0899-5362(02)00154-9. ISSN 1464-343X.CS1 maint: multiple names: authors list (link) O. Catuneanu, H. Wopfner, P.G ... ISSN 1464-343X.CS1 maint: multiple names: authors list (link) Cj, Van Vuuren (2016-09-22). "A basin analysis of the northern ...
A device producing the phase-conjugation effect is known as a phase-conjugate mirror (PCM). One can interpret optical phase ... Multiple photoionisation, near-simultaneous removal of many bound electrons by one photon. Chaos in optical systems. In these ... Cross-phase modulation (XPM), where one wavelength of light can affect the phase of another wavelength of light through the ... Since the imaginary part of the amplitude contains the phase of the beam, this results in the reversal of phase property of the ...
Stanford S. Penner, Forman A. Williams (Eds) (1962). Detonation and Two-Phase Flow. Academic Press. ISBN 978-0-12-395556-2.CS1 ... ISBN 978-0080420196.CS1 maint: multiple names: authors list (link) CS1 maint: extra text: authors list (link) Paul A. Libby, ... ISBN 978-1461269571.CS1 maint: multiple names: authors list (link) CS1 maint: extra text: authors list (link) Amable Liñán, ... Technivision Services.CS1 maint: multiple names: authors list (link) "Fundamental aspects of solid propellant rockets" (PDF). ...
Victory were excluded after multiple forfeits, all remaining matches were awarded 0-2 losses against them. Source:[citation ... needed] (C) Champion; (Q) Qualified to the phase indicated. Per statistical convention in football, matches decided in extra ...
"Clifton Park Center enters 'Phase Three'". Times Union. Retrieved 6 April 2013. CS1 maint: discouraged parameter (link) " ... "Clifton Park Center Announces Multiple Additions". DCG Development. Archived from the original on 28 June 2013. Retrieved 6 ...
CPT is selectively cytotoxic to the cells replicating DNA during S phase and its toxicity is primarily a result of conversion ... doi:10.1016/0014-4827(91)90534-2. PMID 1995300.CS1 maint: multiple names: authors list (link) Y. Pommier; C. Redon; V.A. Rao; J ... Del Bino G, Lassota P, Darzynkiewicz Z (1991). "The S-phase cytotoxicity of camptothecin". Experimental Cell Research. 193 (1 ...
S2CID 44474830.CS1 maint: multiple names: authors list (link) Kinetics of Phase Separation Kinetic theory Non-equilibrium ... His research is reported to have studied the effects of confined geometries and the role of defects in phase separation ... Puri has also guided several students in their studies and serves as the associate editor of Phase Transitions journal of ... S2CID 43652778.CS1 maint: multiple names: authors list (link) Prabhat K. Jaiswal, Sanjay Puri, Subir K. Das (2010). "Kinetics ...
Phase 2: Evobrutinib for multiple sclerosis. ABBV-105 for systemic lupus erythematosus (SLE) Fenebrutinib (GDC-0853, RG7845) ... Phase 1: ONO-4059 for non-Hodgkin lymphoma and/or CLL. Renamed GS-4059 and now in trial NCT02457598. Spebrutinib (AVL-292, CC- ... Clinical trial number NCT01659255 for "ONO-4059 Phase I Dose-escalation Study to Investigate the Safety and Tolerability of ONO ... June 2019). "Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis". N. Engl. J. Med. 380 (25): 2406-2417. ...
... multiple names: authors list (link) Stephen Trimble (March 15, 2018). "GE9X enters flight test phase". Flightglobal. ... A second phase, of 18 flights, began on December 10 to evaluate the software and hot-and-high performance until the first ... In early May, the first flight test phase of two was wrapped up after 18 flights and 110 hours: after checking the aircraft and ... Stephen Trimble (May 29, 2018). "GE9X completes first phase of flight testing". Flightglobal. Norris, Guy (May 20, 2016). " ...
It is better to abandon such concepts as 'pure substance' or 'solute' in such cases and speak of phases instead. The study of ... Chemists generally steered away from anything that did not seem to follow Dalton's laws of multiple proportions; and the ... and phase diagrams were developed. Despite all this progress, the nature of intermetallic compounds and alloys largely remained ... such phases has traditionally been more the domain of metallurgy than of chemistry, although the two fields overlap ...
Phase 2: *Evobrutinib for Multiple Sclerosis. [8]. *Phase 1: *ONO-4059 for Non-Hodgkin's Lymphoma and/or CLL.[9] Renamed GS- ... Clinical trial number NCT01659255 for "ONO-4059 Phase I Dose-escalation Study to Investigate the Safety and Tolerability of ONO ... "Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis." NEJM 2019. https://www.nejm.org/doi/full/10.1056/ ...
However, temperature and pressure are independent only for a single-phase system; for a multiphase system (such as a mixture of ... OCLC 992798629.CS1 maint: multiple names: authors list (link) Cengel, Yunus A.; Boles, Michael A. (2008). Thermodynamics: an ... e.g., boiling point (temperature) depends on elevation (ambient pressure)). Gibbs' Phase Rule Moran, Michael J., author. ... OCLC 993882550.CS1 maint: multiple names: authors list (link) v t e. ...
In the unextended Standard Model, the transition from the electroweak epoch was not a first or a second order phase transition ... doi:10.1103/PhysRevD.93.025003.CS1 maint: multiple names: authors list (link) Bergerhoff, Bastian; Wetterich, Christof (1998 ... "Electroweak Phase Transition in the Early Universe?". Current Topics in Astrofundamental Physics: Primordial Cosmology. ... many extensions to the standard model including supersymmetry and the inert double model have a first order electroweak phase ...
... who divided the first year of life into a coenesthetic phase of the first six months, and then a diacritic phase for the second ... "The Principles of Multiple Function: Observations on Over-Determination." The Psychoanalytic Quarterly 5:45-62. doi:10.1080/ ... "phase before the development of the Oedipus complex." Freud's theories, however, characterized no such phase. According to ... Archived from the original (PDF) on 2019-02-26.CS1 maint: multiple names: authors list (link) De Maat, Saskia, Frans de Jonghe ...
Phase III. Transportation Research Board, Washington, DC.CS1 maint: multiple names: authors list (link) Jonsson, T. (2005). " ... That is to say, the crash rate per cyclist goes down as the cycle volume increases.CS1 maint: multiple names: authors list ( ... The research assessed as part of this study is strongly suggestive that a safety in numbers effect exists.CS1 maint: multiple ... Confirmation is found for the existence of a 'safety-in-numbers' effect for different types of road users.CS1 maint: multiple ...
Sirukumab is in multiple phase 3 trials. Agents in pre-clinical development include ARGX-109, FE301, and FM101. During the ... In phase I/II trial of tocilizumab in ovarian cancer EGFR pathway upregulation was observed and after inhibition of this ... New research has found IL-6 to be an anti-inflammatory cytokine with multiple beneficial effects when released by contracting ... Siltuximab was also tested in the phase I/II study for therapy of patients with metastatic castration-associated prostate ...
The next phase was the exploratory caravels. As Iberians began questing for more than what was immediately tradable off their ... When looking in a textbook one may see an array of multiple names for ships in this century, but in reality many of these ships ... The ship that truly launched the first phase of the discoveries along the African coast was the Portuguese caravel. Iberians ... It is helpful to look at caravels in three phases of maritime vessels: early caravels, exploring caravels and fleet caravels. ...
doi:10.1103/RevModPhys.58.977.CS1 maint: multiple names: authors list (link) B. I. Shraiman; E. D. Siggia (1989). "Spiral phase ...
The initial phase introduces multiple nicks in the phosphodiester backbone. The second phase produces acid-soluble nucleotides ... The third phase, which is the terminal phase, consists of hyperchromic shift resulting from reduction of oligonucleotides. ... The action of DNase occurs in three phases. ...
Used primarily in the synthesis of medicinal drugs, solution-phase combinatorial chemistry allows for the creation of large ... doi:10.1016/S0040-4039(00)01999-7.CS1 maint: multiple names: authors list (link) Garcia, J. Gabriel (2003). "Scavenger Resins ... Polymer-supported reductions and oxidations with increased efficiency Scavenger Resins in Solution-Phase CombiChem High-loading ... Employment of scavenger resins has become increasingly popular in solution-phase combinatorial chemistry. ...
Cite journal requires ,journal= (help) Bella J, Rossmann MG (1998). "A General Phasing Algorithm for Multiple MAD and MIR Data ... Guss JM, Merritt EA, Phizackerley RP, Hedman B, Murata M, Hodgson KO, Freeman HC (1989). "Phase determination by multiple- ... MAD phasing - an in depth tutorial with examples, illustrations, and references. HHMI Bio for Wayne Hendrickson Wayne ... de la Fortelle E, Bricogne G (1997). "Maximum-Likelihood Heavy-Atom Parameter Refinement for Multiple Isomorphous Replacement ...
Main ISO phases of LCA[edit]. This section has multiple issues. Please help improve it or discuss these issues on the talk page ... CS1 maint: multiple names: authors list (link) *^ a b c d e f g h Hauschild, Michael Z., Ralph K. Rosenbaum, & Stig Irving ... The phases are often interdependent, in that the results of one phase will inform how other phases are completed. Therefore, ... Cradle-to-grave is the full Life Cycle Assessment from resource extraction ('cradle') to use phase and disposal phase ('grave ...
The late phase of sepsis is characterized by an increased microbiological burden and death rate. Critical Care. July 2011, 15 ( ... Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, Jöhrer K. T cells in multiple ... Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. December 2011, 306 (23): 2594-605. PMC ... Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. Immunology Letters. March 2017 ...
Success is much better for Phase 2 than for Phase 1 - approximately 90 percent benefit from the second phase, and the success ... In the recent years, many surgeons have tried to address the multiple levels of obstruction by performing multiple procedures ... Note that genioglossus advancement can be performed either during Phase 1 or Phase 2 surgeries. Phase 2 involves ... There is debate among surgeons as to the role of Phase 1 surgery. In 2002, an Atlanta-based surgical team, led by Dr. Jeffrey ...
CS1 maint: multiple names: authors list (link). *^ Gene C. Palmer (September 2001). "Neuroprotection by NMDA receptor ...
CS1 maint: multiple names: authors list (link). *^ a b c d e Gorski, D. (2010-08-03). "Credulity about acupuncture infiltrates ... was reported as showing that the medical profession had responded to the growth of CAM in three phases, and that in each phase ... multiple studies have shown significantly worse outcomes if patients turn to alternative therapies. While this may be because ...
Allergic Sensitization - There is an acute response (early stages) and a late-phase response (later stages). In the early ... and some medically unexplained syndromes such as fibromyalgia and multiple chemical sensitivity. Sensitization may also ...
Recovered gorilla carcasses have contained multiple Ebola virus strains, suggesting multiple introductions of the virus. Bodies ... The response to the epidemic then moved to a second phase, as the focus shifted from slowing transmission to ending the ... January 2004). "Multiple Ebola virus transmission events and rapid decline of central African wildlife". Science. 303 (5656): ...
During the depression phase, the inspiratory burst changes from an augmenting bell-shaped burst to a decrementing burst, a ... Abdala AP, Rybak IA, Smith JC, Zoccal DB, Machado BH, St-John WM, Paton JF (June 2009). "Multiple Pontomedullary Mechanisms of ... Blocking this inhibition from Glycine or GABA causes it's neurons to be incapable of switching from the active phase to the ... Rubin JE, Shevtsova NA, Ermentrout GB, Smith JC, Rybak IA (April 2009). "Multiple Rhythmic States in a Model of the Respiratory ...
Late Harappan Phase, c. 1800 - 1300 BC.. By far the most exquisite and obscure artifacts unearthed to date are the small, ... Pages using multiple image with auto scaled images. *Commons category link is on Wikidata ... with clay brick houses at its greatest extent during the Mature Harappan phase (2600 BC - 1900 BC), which is considered large ...
Multiple hominid groups coexisted for some time in certain locations. Homo neanderthalensis were still found in parts of ... This was a lunar calendar that was used to document the phases of the moon. Genuine solar calendars did not appear until the ... The Paleolithic was an extended period of time, during which multiple technological advances were made, many of which had ...
CS1 maint: multiple names: authors list (link). *. Amos SW, James MR (1999). Principles of Transistor Circuits. Butterworth- ... The ASEA Brown Boveri (ABB) 5SNA2400E170100 ,[82] intended for three-phase power supplies, houses three n-p-n IGBTs in a case ... Multiple-base transistor, used to amplify very-low-level signals in noisy environments such as the pickup of a record player or ... Multiple-emitter transistor, used in transistor-transistor logic and integrated current mirrors ...
They work by killing C. acnes and reducing inflammation.[20][82][90] Although multiple guidelines call for healthcare providers ... Results of a Phase 2, Dose-Ranging Study". Journal of Drugs in Dermatology. 17 (3): 333-338. PMID 29537451.. ... Microneedling is a procedure in which an instrument with multiple rows of tiny needles is rolled over the skin to elicit a ... Phase 3, Randomized, Double-Blind Clinical Trials". Journal of Drugs in Dermatology. 17 (9): 987-996. PMID 30235387.. ...
CS1 maint: Multiple names: authors list (link) *^ "Why San Diego Has Biotech", Fikes, Bradley J. San Diego Metropolitan, April ... CS1 maint: Multiple names: authors list (link) *^ A. Razzaque Ahmed, M.D.; Zachary Spigelman, M.D.; Lisa A. Cavacini, Ph.D.; ... CS1 maint: Multiple names: authors list (link) *^ Shanafelt TD, Madueme HL, Wold RC, Tefferi A (2003). "Rituximab for Immune ... McGinley, MP; Moss, BP; Cohen, JA (January 2017). "Safety of monoclonal antibodies for the treatment of multiple sclerosis". ...
232] [233] A fire detection malfunction obviously caused the testing phase to be aborted prematurely.[234] Christoph Schaefer ... Revised plans called for multiple systems controlled by 90 km (56 mi) of wiring. By 19 May 2014 Siemens had not yet designed ... During much of the planning and construction phase the new airport was known as Berlin Brandenburg International Airport, ... Deutsche Bahn confirmed in August 2011 that multiple daily Intercity-Express and InterCity trains will connect the airport to ...
... but tailfins bore one of multiple designs.[143] Several people spoke out against the change, including the former prime ... having originally intended to phase out the remaining 747s in 2024. The airline stated that their decision to bring forward the ...
In order to attain data about the spatial pattern of network activity they developed what they call phase profiles (PPs), which ... Baruchi I, Ben-Jacob E (2007). "Towards Neuro-Memory Chip: Imprinting Multiple Memories in Cultured Neural Networks". Physical ...
CS1 maint: Multiple names: authors list (link). *^ a b Nikolai Dotzek (2003-03-20). "An updated estimate of tornado occurrence ... as well as whether the ENSO phase is that of El Niño or La Niña.[90] Research has found that fewer tornadoes and hailstorms ... CS1 maint: Multiple names: authors list (link). *^ Dave Zittel (2000-05-04). "Tornado Chase 2000". USA Today. Archived from the ... CS1 maint: Multiple names: authors list (link). *^ National Weather Service (2009-02-06). "What is SKYWARN?". National Oceanic ...
CS1 maint: Multiple names: authors list (link) *^ a b Dawkins, Richard; Krebs, J. R. (1979). "Arms Races between and within ... CS1 maint: Multiple names: authors list (link) *^ a b Stoltzfus, Arlin (1999). "On the Possibility of Constructive Neutral ... CS1 maint: Multiple names: authors list (link) *^ Maughan, H.; Masel, J.; Birky, W. C.; Nicholson, W. L. (2007). "The roles of ... CS1 maint: Multiple names: authors list (link) *^ Adami, C.; Ofria, C.; Collier, T. C. (2000). "Evolution of biological ...
BEIR VII Phase 2. Washington, DC: The National Academies Press. ISBN 0-309-09156-X.. CS1 maint: Multiple names: authors list ( ... CS1 maint: Multiple names: authors list (link) *^ a b c Villanueva-Russell Y (June 2011). "Caught in the crosshairs: identity ... CS1 maint: Multiple names: authors list (link) *^ a b Anderson-Peacock E, Blouin JS, Bryans R, Danis N, Furlan A, Marcoux H, ... CS1 maint: Multiple names: authors list (link) *^ a b Goto, Viviane; Frange, Cristina; Andersen, Monica L.; Júnior, José M. S ...
CS1 maint: Multiple names: authors list (link). *^ "Standard Test Method for Extracting Residue from Metallic Medical ... When in the initial R&D phase, manufacturers are now beginning to design for manufacturability. This means products can be more ... Incorporation of the guidelines during the development phase of such apps can be considered as developing a medical device; the ... CS1 maint: Multiple names: authors list (link). [page needed] *^ http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures ...
Upon impact, his hood pins severed, causing it to open and slam up against the windshield multiple times. As Michael Waltrip ... with the Hutchens device being phased out in 2005, leaving only the HANS device.[48] ...
This occurs because the phase accumulated in the layer relative to the phase of the light immediately reflected decreases as ... In the more complicated scenario of multiple reflections, say with light travelling through a window, light is reflected both ... thus accumulating more phase of their own) to arrive at the interface. The net effect is that the relative phase is actually ... This is counterintuitive, since the ray experiences a greater total phase shift in the layer than for normal incidence. This ...
The government's petition argued that the Ninth Circuit needed to act to correct "multiple and clear errors of law in refusing ... The government also argued that the pre-trial discovery phase would cause the government harm due to the volume of data and ... One motion stated that the case, in addressing multiple government agencies, violated the Administrative Procedure Act, while ...
Multiple metastatic tumors are generally treated with radiotherapy and chemotherapy rather than surgery and the prognosis in ... Secondary tumors of the brain are very common in the terminal phases of patients with an incurable metastasized cancer; the ... In standard external beam radiation therapy, multiple treatments of standard-dose "fractions" of radiation are applied to the ... multiple endocrine neoplasia, and neurofibromatosis type 2 carry a high risk for the development of brain tumors.[21][22] ...
Certain antiandrogens combine multiple of the above mechanisms.[5][68] An example is the steroidal antiandrogen cyproterone ... a phase III randomised trial". Br J Urol. 52 (3): 208-15. doi:10.1111/j.1464-410x.1980.tb02961.x. PMID 7000222.. ...
Electronic phases. Electronic band structure · Plasma · Insulator · Mott insulator · Semiconductor · Semimetal · Conductor · ... CS1 maint: multiple names: authors list (link) *^ Poole, Jr., Charles P. (2007). Superconductivity (2nd ed.). Amsterdam: ... Magnetic phases. Diamagnet · Superdiamagnet. Paramagnet · Superparamagnet. Ferromagnet · Antiferromagnet. Metamagnet · Spin ... However, other forms of magnetism (such as ferromagnetism or paramagnetism) are so much stronger that, when multiple different ...
Moreover, a tectonic obstacle also played a role in the damming of the lakes during the very last degradation phases of the ... and it was he who made first attempts to gain chief hydraulic characteristics of the Missoula floods according to the multiple ... Then these correctly summarised data must be compared with various phases of the contemporary mountainous alluvium at the ... the phase of the rogen moraine according to the classification by Yu. A. Lavrushin. B.A. Borisov and E.A. Minina ascribed the ...
As can be seen by the arbitrary 100-year ranges, the dating of the phases is highly schematic. The phases are based on ... In the tumulus-period, multiple inhumations under barrows were common, at least for the upper levels of society. In the ... In the earliest phases of the Urnfield period, man-shaped graves were dug, sometimes provided with a stone lined floor, in ... The Urnfield culture covers the phases Hallstatt A and B (Ha A and B) in Paul Reinecke's chronological system, not to be ...
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to ... Each cycle evolves in two phases: The phase of production of new mental units in the first half and their alignment in the ... The theory of multiple intelligences. New York: Basic Books. *^ Furth, H. G., & Wachs, H. (1975). Thinking goes to school: ... In the stages beyond formal, more complex behaviors characterize multiple system models.[citation needed] ...
Despite all his faults, says Daniels, "he made enormous contributions to the natural history phase of American science...with ... Chambers 1992. sfn error: multiple targets (2×): CITEREFChambers1992 (help) *^ Jackson & Rose 2009 ...
These high temperature phases would last for two days or more and would repeat several times in any given experiment once they ... 814-815 "After several years and multiple experiments by numerous investigators, most of the scientific community now considers ... The calculated power leaving the cell was significantly higher than the input power during these high temperature phases. ... Eventually the high temperature phases would no longer occur within a particular cell.[27] ...
Phase 4 (Palisades) - Thursday, September 10, 2015 , Thursday, February 1, 2018 at Palisades, Washington DC, Washington, DC. ... Now that the first three Phases have been completed and weight loss has been achieved, it is time to enjoy the freedom that you ... We couldnt process your order because you have this event open on multiple tabs in your browser. Please try again with only ... Have questions about Ideal Protein Maintenance - Phase 4 (Palisades)? Contact Ideal Body Wellness ...
Multiple pathways in pressure-induced phase transition of coesite. Wei Liu, Xuebang Wu, Yunfeng Liang, Changsong Liu, Caetano R ... It transforms into α-PbO2 phase when it is relaxed under further compression. We show that the HPO phase forms through a ... including the one leading to an HPO phase. This octahedral phase has an oxygen hcp sublattice featuring 2 × 2 zigzag octahedral ... However, it was found to transform into a high-pressure octahedral (HPO) phase, or coesite-II and coesite-III. Given that the ...
The work concerned the final design, construction, and operation of a pilot plant for demonstrating Multiple Phase Ejector (MPE ... Multiple Phase Ejector Pilot Plant One of 197 reports in the series: Office of Saline Water Reports available on this site. ... Leigh, John H. Multiple Phase Ejector Pilot Plant, report, June 1970; Washington D.C.. (digital.library.unt.edu/ark:/67531/ ... The work concerned the final design, construction, and operation of a pilot plant for demonstrating Multiple Phase Ejector (MPE ...
Infrared laser multiple photon excitation/dissociation of Thiophene (Th) was studied as a function of Th pressure, laser pulse ... Infrared laser multiple photon excitation/dissociation of Thiophene (Th) was studied as a function of Th pressure, laser pulse ...
GeNeuro Announces First Patients Treated in Phase 2b Study for Multiple Sclerosis CHANGE-MS clinical study plans to enroll 260 ... About Multiple Sclerosis Multiple sclerosis (MS) is an autoimmune disease affecting approximately 2.5 million people worldwide ... Phase IIb study in relapsing-remitting multiple sclerosis (RRMS). GNbAC1, the first drug candidate in clinical studies directly ... "The aim of this Phase 2b study is to demonstrate the efficacy of GNbAC1 as a treatment for MS patients. This new therapeutic ...
The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the ... such multiple-phase systems include an aqueous phase and a solid phase, or an aqueous phase and an oil (lipid) phase, or an ... The phase other than the aqueous phase may be one or more oil (lipid) phases or one or more solid phases, or multiple different ... A solid phase in the oil phase of an emulsion passes from the solid phase to the oil phase to the aqueous phase. By regulating ...
Multiple,Sclerosis,Trial,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest ... for multiple sclerosis. In addition to multiple sclerosis, Artielle is also conducting research in various pre-clinical phases ... Announces Successful Phase Ib Results for DOV 21,947. 9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical ... BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine. 4. Dendreon Announces Publication of Phase 1 ...
About the Phase 1 R/R MM Trial. The objective of this multicenter, open-label, Phase 1 dose-escalation study is the ... CLR 131 is in a Phase 2 clinical study in R/R MM and a range of B-cell malignancies, and a Phase 1 clinical study in patients ... The company plans to initiate a Phase 1 study with CLR 131 in pediatric solid tumors and lymphoma, as well as a second Phase 1 ... The companys lead PDC therapeutic, CLR 131, is in a Phase 1 clinical study in patients with R/R MM and a Phase 2 clinical ...
Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase BMJ 2011; 342 :d199 ... Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase. BMJ 2011; 342 doi: ... Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase ... Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase ...
Purchase Measurement of the Thermodynamic Properties of Multiple Phases, Volume 7 - 1st Edition. Print Book & E-Book. ISBN ... Measurement of the Thermodynamic Properties of Multiple Phases, Volume 7 1st Edition. 0.0 star rating Write a review ... Describes the latest techniques for studying multiple phases of pure component systems, using quantities, units and symbols as ... Measurement of Thermodynamic Properties of Multiple Phases, Volume VII is an invaluable reference source to researchers and ...
Trial Phase:. Phase 1. Minimum Age:. N/A. Maximum Age:. N/A ... A Phase 1 Study of Bevacizumab in Combination With 1) Sunitinib ... A Phase 1 Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and ... MTD defined by Dose Limiting Toxicity in first 28 day cycle (induction phase) ...
Strong electronic interaction and multiple quantum Hall ferromagnetic phases in trilayer graphene. *Biswajit Datta1. *, Santanu ... Strong electronic interaction and multiple quantum Hall ferromagnetic phases in trilayer graphene. Nat. Commun. 8, 14518 doi: ... Tunable symmetries of integer and fractional quantum Hall phases in heterostructures with multiple Dirac bands. . Phys. Rev. ... Landau level splittings, phase transitions, and nonuniform charge distribution in trilayer graphene. . Phys. Rev. Lett. 117, ...
AZD6244 has on participants and their multiple myel... ... A Phase 2 Study of AZD6244 in Multiple Myeloma. 2014-08-27 03: ... Home » Topics » Multiple Myeloma » Research » A Phase 2 Study of AZD6244 in Multiple Myeloma ... More From BioPortfolio on "A Phase 2 Study of AZD6244 in Multiple Myeloma". *Related Companies*Related Events*Related Clinical ... Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT.. A 60-year-old woman diagnosed with multiple myeloma was ...
MSD announced the results of their Phase III study of vorinostat at the 53rd Annual Meeting of the American Society of ... Home » Multiple Myeloma Phase III Trial - Vorinostat Achieved Primary Endpoint. Multiple Myeloma Phase III Trial - Vorinostat ... Vorinostat, designed for treatment in patients with progressive multiple myeloma, has met its primary endpoint in a Phase III ... MSD announced the results of their Phase III study of vorinostat at the 53rd Annual Meeting of the American Society of ...
Clinical Trial, Phase III; Comparative Study; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Govt ... Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.. Randomized controlled trial Fox RJ, et al ... Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. Randomized controlled trial ... METHODS: In this phase 3, randomized study, we investigated the efficacy and safety of oral BG-12, at a dose of 240 mg two or ...
Multiple Myeloma Myeloma, Plasma-Cell PLASMACYTOMA Biological: milatuzumab Phase 1 Phase 2 ... Phase I/II Study of hLL1 in Multiple Myeloma. The safety and scientific validity of this study is the responsibility of the ... This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who ... A Phase I/II Study of Immunotherapy With hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients With Multiple ...
PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the ... Results from the Phase 1 and 2 portions of CHAMPION were presented for 104 patients (Phase 1, n=15; Phase 2, n=89) with ... The ARROW (RAndomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving ... Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple ...
Liquid Phase Transition: A Deluge of Data Points to Multiple Regulators. Quick Links. *Article ... Nuclear Import Receptor Inhibits Phase Separation of FUS through Binding to Multiple Sites. Cell. 2018 Apr 19;173(3):693-705. ... Protein Phase Separation: A New Phase in Cell Biology. Trends Cell Biol. 2018 Mar 27;. PubMed. ... Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Mol Cell. 2017 Mar 16;65(6):1044-1055.e5. ...
Dps Protects Cells against Multiple Stresses during Stationary Phase Message Subject (Your Name) has forwarded a page to you ... Dps Protects Cells against Multiple Stresses during Stationary Phase. Sudha Nair, Steven E. Finkel ... Dps has been shown to protect cells from oxidative stress during exponential-phase growth. During stationary phase, Dps ... We also show that during stationary phase Dps protects the cell not only from oxidative stress but also from UV and gamma ...
Dps Protects Cells against Multiple Stresses during Stationary Phase Message Subject (Your Name) has forwarded a page to you ... Dps Protects Cells against Multiple Stresses during Stationary Phase. Sudha Nair, Steven E. Finkel ... Comparison of lag phases of wild-type (WT) and dps mutant cells from 1-day-old stationary-phase cultures. Shown is a ... Metal stress during stationary phase and log phase. Wild type (WT; squares) or dps (circles) cells were treated with either ...
Nokia sites use cookies to improve and personalize your experience and to display advertisements. The sites may also include cookies from third parties. By using this site, you consent to the use of cookies. Learn more ...
Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. Martina Absinta,1,2 Pascal Sati,1 ... Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol. 2013;74( ... A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler. 2013;19(1 ... Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study ...
Although sniffing and whisking showed phase locking at multiple modes, the preferred phase of coordination of these two rhythms ... we also observed multimode phase locking with multiple whisks within a sniff cycle or multiple sniffs within a whisk cycle- ... Multiple Modes of Phase Locking between Sniffing and Whisking during Active Exploration. Sachin Ranade, Balázs Hangya and Adam ... Multiple modes of phase locking between sniffing and whisking. Coherence between sniffing and whisking informs us about the ...
E-mail a copy of With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug to a friend. ... Separate multiple entries with a comma. Maximum 5 entries. Friends E-Mail: *. Separate multiple entries with a comma. Maximum ... Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma ...
... today announced that the first patient has been enrolled in the phase 2 PORT study. The study,... ... and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 ... Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in ... In the pivotal phase 2 HORIZON study melflufen plus dexamethasone demonstrated encouraging efficacy and a clinically manageable ...
Movement Therapy Education presents Phase 2 - Module 5 - Clinical Assessment - Ankle/Foot - Liverpool - Tuesday, 10 September ... Phase 2 - Module 5 - Clinical Assessment - Ankle/Foot - Liverpool at Clinic-al 79 Sandon Road, Southport, PR8 4QD, United ... Phase 2 - Module 5 - Clinical Assessment - Ankle/Foot - Liverpool. by Movement Therapy Education ... This course is split into two parts (Part a and b) and forms part of Phase 2 of the Musculoskeletal Remedial and Exercise ...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today enrollment of the first patient in the C
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM). The safety and scientific validity of this study ... Study Phase ICMJE Phase 2 Study Design ICMJE Allocation: N/A. Intervention Model: Single Group Assignment. Masking: None (Open ... Advanced Multiple Myeloma Intervention ICMJE *Drug: Filanesib, KSP (Eg5) inhibitor; intravenous multiple dose, single schedule ... The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent ...
... multiple myeloma (MM) patients. Lenalidomide has shown efficacy in combination with bortezomib and dexamethasone but this ... We conducted this phase 2 study (clinicaltrials.gov identifier: NCT01160484) to evaluate whether a longer 4-week schedule using ... A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ... Results of a phase III trial of deutsche studiengruppe multiples myeloma, showing efficacy and safety of RAD regimen (Revlimid ...
... in the relief of spasticity in people with Multiple Sclerosis (MS). This study is one of a number of Phase III studies which ... today announces preliminary results from a Phase III study of Sativex® ... Phase III Multiple Sclerosis spasticity study 17/03/2006 GW to evaluate optimal regulatory filing strategy with marketing ... Preliminary Results from Sativex® Phase III Multiple Sclerosis spasticity Preliminary Results from Sativex® Phase III Multiple ...
  • GeNeuro (Paris: GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), today announced that the first patients have been treated with its lead product, GNbAC1, in a Phase IIb study in relapsing-remitting multiple sclerosis (RRMS). (businesswire.com)
  • Multiple sclerosis (MS) is an autoimmune disease affecting approximately 2.5 million people worldwide, according to the Multiple Sclerosis Foundation. (businesswire.com)
  • PORTLAND, Ore., Sept. 14 /PRNewswire/ -- Artielle ImmunoTherapeutics, a clinical stage biopharmaceutical company announced today the presentation of "Results of a Phase 1 safety study of RTL1000, a recombinant T-Cell receptor ligand specific for an immunodominant MOG peptide, in multiple sclerosis. (bio-medicine.org)
  • these were to determine the pharmacokinetic profile of RTL1000 and assess immunologic parameters in a subset of Multiple Sclerosis (MS) patients. (bio-medicine.org)
  • Worldwide, multiple sclerosis (MS) is thought to affect more than 2.5 million people. (bio-medicine.org)
  • The company has recently completed Phase 1 clinical safety trial for lead drug candidate, RTL1000, for multiple sclerosis. (bio-medicine.org)
  • In addition to multiple sclerosis, Artielle is also conducting research in various pre-clinical phases on other autoimmune disease to which its platform technology is applicable such as celiac disease, uveitis, rheumatoid arthritis, type 1 diabetes and other diseases. (bio-medicine.org)
  • Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. (nih.gov)
  • BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate). (nih.gov)
  • In this phase 3, randomized study, we investigated the efficacy and safety of oral BG-12, at a dose of 240 mg two or three times daily, as compared with placebo in patients with relapsing-remitting multiple sclerosis. (nih.gov)
  • In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo. (nih.gov)
  • Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. (nih.gov)
  • European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. (nih.gov)
  • Dimethyl fumarate for multiple sclerosis. (nih.gov)
  • Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate]. (nih.gov)
  • They also report that arginine methylation inhibits phase transition of FUS, and that these pathways go awry in some cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). (alzforum.org)
  • Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. (nih.gov)
  • To evaluate the efficacy and safety of BHT-3009 in relapsing-remitting multiple sclerosis (MS) and to confirm that BHT-3009 causes immune tolerance. (nih.gov)
  • Porton Down, UK, 17 March 2006 - GW Pharmaceuticals plc (AIM: GWP) today announces preliminary results from a Phase III study of Sativex® in the relief of spasticity in people with Multiple Sclerosis (MS). This study is one of a number of Phase III studies which are currently taking place to support approval of Sativex across Europe in a range of target indications. (rutgers.edu)
  • NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the multicenter Phase 2 trial evaluating ublituximab, the Company's investigational, glycoengineered, anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS), in the Multiple Sclerosis Journal . (globenewswire.com)
  • Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer stated, "We are extremely pleased to see the ublituximab Phase 2 results published in Multiple Sclerosis Journal . (globenewswire.com)
  • Edward Fox, MD, PhD, Director of the Multiple Sclerosis Clinic of Central Texas at Central Texas Neurology Consultants, Clinical Associate Professor at the University of Texas Dell Medical School in Austin, TX and the Principal Investigator for this Phase 2 study stated, "The encouraging clinical data we have published illustrate the potential for ublituximab in the treatment of patients with relapsing forms of multiple sclerosis. (globenewswire.com)
  • These data are described further in the manuscript entitled, "A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis", which was published yesterday in Multiple Sclerosis Journal . (globenewswire.com)
  • Each trial is a global, randomized, multi-center, double-blinded, double-dummy, active-controlled study comparing ublituximab (TG-1101), to teriflunomide in subjects with relapsing forms of Multiple Sclerosis (RMS). (globenewswire.com)
  • NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX ), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced the final results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). (yahoo.com)
  • The data were presented yesterday at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting held in Dallas, TX. (yahoo.com)
  • The data was previously presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting held in October of 2018. (yahoo.com)
  • Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. (yahoo.com)
  • Multiple sclerosis is an immune disorder in which the body mistakenly attacks the myelin sheath surrounding nerve fibers in the brain and spinal cord. (oregonbio.org)
  • OTCQX: RHHBY) today announced positive results from a pivotal Phase III study that evaluated the investigational medicine ocrelizumab in people with primary progressive multiple sclerosis (PPMS). (roche.com)
  • Multiple sclerosis (MS) is a chronic disease that affects an estimated 2.3 million people around the world, for which there is currently no cure. (roche.com)
  • Today Biogen Idec (NASDAQ: BIIB) announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date. (thestreet.com)
  • These data were presented at the 28 th Congress of the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) in Lyon, France. (thestreet.com)
  • In a pre-specified analysis of integrated, or pooled, data from the Phase 3 DEFINE and CONFIRM studies, dimethyl fumarate showed statistically significant and clinically relevant effects in reducing multiple sclerosis (MS) relapses and progression of disability, as well as reductions in magnetic resonance imaging (MRI) measures of disease activity. (thestreet.com)
  • Clinical Effects of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies was available for viewing on Thursday, Oct. 11, 2012 from 3:30-5:00 p.m. (thestreet.com)
  • Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies will be presented by Prof. Ralf Gold on Friday, Oct. 12, 2012 at 2:40 p.m. (thestreet.com)
  • BTG plc (LSE: BGC), the life sciences company, today announces that its licensee, Genzyme Corporation, and Bayer Schering Pharma AG have initiated a pivotal phase III trial of Campath ® (alemtuzumab) as a treatment for multiple sclerosis. (btgplc.com)
  • Louise Makin, BTG's CEO, commented: "We are excited by the prospects of Campath in multiple sclerosis and delighted that the pivotal phase III trials are under way. (btgplc.com)
  • Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS). (btgplc.com)
  • Results of the primary outcomes from this trial at 36 months are expected to be presented on Oct. 14 by Professor Alastair Compston during the Charcot Award lecture at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis, in Prague. (btgplc.com)
  • Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) in which the immune system can attack the brain and spinal cord. (btgplc.com)
  • Welcome to This is MS, the leading forum for Multiple Sclerosis research and support. (thisisms.com)
  • Multiple sclerosis (MS) is a CNS disease characterized by. (thisisms.com)
  • Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3. (thisisms.com)
  • Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. (thisisms.com)
  • CAMBRIDGE, Mass., Oct. 3 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases. (bio-medicine.org)
  • Following establishment of safety at potentially therapeutic doses, the Company will initiate its first repeat dose study in multiple sclerosis patients in early 2008. (bio-medicine.org)
  • PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, has shown to be more potent and effective than Copaxone(R) in treating disease models for multiple sclerosis. (bio-medicine.org)
  • The goal for PI-2301 is to enhance the therapeutic benefit of a proven compound class in multiple sclerosis and give neurologists a new weapon as a primary treatment for patients with this debilitating disease. (bio-medicine.org)
  • Over 400,000 Americans have multiple sclerosis (MS), and worldwide MS may affect over 2.5 million individuals. (bio-medicine.org)
  • The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. (bio-medicine.org)
  • In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated with better efficacy than placebo on MRI measures and was well tolerated. (thisisms.com)
  • The RADIANCE phase 3 study aimed to confirm the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multiple sclerosis. (thisisms.com)
  • METHODS: We did a 24-month, multicentre, double-blind, double-dummy phase 3 trial in participants with relapsing multiple sclerosis at 147 medical centres and clinical practices in 21 countries. (thisisms.com)
  • Participants were aged 18-55 years, had multiple sclerosis according to 2010 McDonald criteria, a relapsing clinical course, brain MRI lesions consistent with multiple sclerosis, an expanded disability status scale score of 0·0-5·0, and either at least one relapse within 12 months before screening or at least one relapse within 24 months before screening plus at least one gadolinium-enhancing lesion within the 12 months before randomisation. (thisisms.com)
  • INTERPRETATION: In this 24-month phase 3 study in participants with relapsing multiple sclerosis, ozanimod was well tolerated and associated with a significantly lower rate of clinical relapses than intramuscular interferon beta-1a. (thisisms.com)
  • These findings show the potential of ozanimod as an effective oral therapy for individuals with relapsing multiple sclerosis. (thisisms.com)
  • BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-remitting multiple sclerosis. (nih.gov)
  • We conducted a randomized, double-blind, placebo-controlled phase 3 study involving patients with relapsing-remitting multiple sclerosis. (nih.gov)
  • In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI. (nih.gov)
  • A study published in the journal Neurology reveals that stem cell transplantation could be a more effective therapy in severe cases of multiple sclerosis (MS) than the drug mitoxantrone. (cancerconnect.com)
  • The study is entitled " Autologous hematopoietic stem cell transplantation in multiple sclerosis . (cancerconnect.com)
  • METHODS For 2 years 53 patients with clinically definite relapsing-remitting multiple sclerosis with disease duration 1-5 years and expanded disability status scale⩽5.0 at baseline were monitored. (bmj.com)
  • CONCLUSIONS In the early phase of relapsing-remitting multiple sclerosis the cognitive deterioration relies more on the development of brain parenchymal volume atrophy than on the extent of burden of disease in the brain. (bmj.com)
  • Objective To investigate the relationship among cortical radiologic changes, the number of early relapses (ERs), and the long-term course of multiple sclerosis (MS). (neurology.org)
  • BTG plc (LSE: BGC), the specialist healthcare company, is pleased to note the announcement by Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme of positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif ® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS). (btgplc.com)
  • Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif ® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS). (btgplc.com)
  • "In this 2-year comparative study, the effect of alemtuzumab on reducing relapses versus Rebif, a leading drug for the treatment of Multiple Sclerosis, is impressive, and the safety profile is consistent with the Phase 2 clinical trial experience," saidChristopher A. Viehbacher, Chief Executive Officer, Sanofi. (btgplc.com)
  • We look forward to the results from CARE-MS II, which will provide clinical data in patients whose disease was not adequately controlled on other multiple sclerosis therapies. (btgplc.com)
  • Today's results are an important step forward in the development of alemtuzumab to address the substantial unmet needs for multiple sclerosis patients. (btgplc.com)
  • Celgene Corporation (NASDAQ:CELG) today announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, in relapsing multiple sclerosis (RMS) were accepted for the MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting, which is being held in Paris, October 25-28, 2017. (ntbinfo.no)
  • Our strong presence at this year's meeting and the breadth of data being presented on ozanimod highlight our commitment to bringing forth ozanimod as a potential novel, oral therapeutic option for people with multiple sclerosis," said Terrie Curran, President, Celgene Inflammation and Immunology. (ntbinfo.no)
  • Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. (yahoo.com)
  • Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. (yahoo.com)
  • The purpose of this study is to evaluate the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice. (bioportfolio.com)
  • This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who have failed at least two prior standard systemic treatments. (clinicaltrials.gov)
  • AMGN ) today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis ® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). (prnewswire.com)
  • Phase 2, n=89) with relapsed or refractory multiple myeloma who had received one to three prior treatment regimens at the determined maximum tolerated dose (MTD) of 20/70 mg/m 2 . (prnewswire.com)
  • The CHAMPION ( C ommunity H armonized A ssessment of M yeloma P atients via an I ntegrated O ncology N etwork) trial is a Phase 1/2, multicenter, single-arm, non-randomized, open-label and dose-escalation study of weekly Kyprolis with dexamethasone for patients with relapsed or refractory multiple myeloma. (prnewswire.com)
  • The study, which is expected to be fully recruited in December 2020 , is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma, RRMM. (prnewswire.com)
  • In the pivotal phase 2 HORIZON study melflufen plus dexamethasone demonstrated encouraging efficacy and a clinically manageable safety profile in heavily pretreated patients with relapsed refractory multiple myeloma, with primarily hematologic Adverse Events (AE) and a low incidence of non-hematologic AEs. (prnewswire.com)
  • Based on the results from the HORIZON study Oncopeptides has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. (prnewswire.com)
  • Our previous studies have shown that lowering the dose of pegylated liposomal doxorubicin (PLD) and bortezomib in combination with intravenous dexamethasone on a longer 4-week cycle maintained efficacy and improved tolerability in both previously untreated and relapsed/refractory (R/R) multiple myeloma (MM) patients. (nature.com)
  • Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. (springer.com)
  • Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. (springer.com)
  • The goal of the Phase I portion of this clinical research study is to find the highest tolerated dose of the combination of thalidomide, lenalidomide, and dexamethasone that can be given to patients with relapsed or refractory MM. The goal of the Phase II portion of this study is to learn if the drug combination can help to control the disease. (mdanderson.org)
  • To determine the maximum tolerated dose (MTD) of the combination of lenalidomide and thalidomide and dexamethasone (LTD) in patients with relapsed/refractory multiple myeloma (RRMM). (mdanderson.org)
  • Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors. (clinicaltrials.gov)
  • THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). (centerwatch.com)
  • CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) " highlights data from 4 subjects in Cohort 6 who received a fractionated dose of 37.5 mCi/m 2 . (benzinga.com)
  • Cohort 6's overall response rate of 50% with 100% disease control in highly chemo-refractory elderly patients highlights CLR 131's potential as a first-in-class targeted radiotherapeutic for relapsed or refractory multiple myeloma. (benzinga.com)
  • Additionally, based on the positive results from Cohort 6, we are now allowed to use the 37.5 mCi/m 2 dosing level in our ongoing Phase 2 (CLOVER-1) study evaluating CLR 131 in patients with relapsed/refractory (R/R) B-cell malignancies and expect data from the Phase 2 trial in Q4 2019. (benzinga.com)
  • It is very encouraging to see consistently high response rates with deepening responses over time for melflufen in combination with proteasome inhibition and anti-CD38 therapies in the ongoing ANCHOR study in patients with relapsed/refractory multiple myeloma. (biospace.com)
  • The updated interim data from ANCHOR that is investigating the combination of melflufen and dexamethasone with either bortezomib or daratumumab in patients with relapsed/refractory multiple myeloma, show very encouraging efficacy both in terms of response rates and emerging durability of the responses. (biospace.com)
  • GSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple myeloma on the basis of a set of strong results from a phase 2 trial. (pharmaphorum.com)
  • GSK is also testing belantamab mafodotin as a third-line monotherapy in relapsed/refractory multiple myeloma and in combination with standard and novel treatments in the first and second line setting. (pharmaphorum.com)
  • It resulted in deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma. (ecancer.org)
  • The 315-patient, open-label study evaluated single-agent Kyprolis® (carfilzomib) for Injection compared to an active control regimen of low-dose dexamethasone, or equivalent corticosteroids, plus optional cyclophosphamide in patients with relapsed and advanced refractory multiple myeloma. (fiercepharma.com)
  • The randomized, open-label Phase 3 FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) trial evaluated single-agent Kyprolis versus an active control regimen of low-dose steroids plus optional cyclophosphamide in patients with relapsed and advanced refractory multiple myeloma following treatment with at least three prior therapies. (fiercepharma.com)
  • Safety data have been evaluated in 526 patients with relapsed and/or refractory multiple myeloma who received single-agent Kyprolis. (fiercepharma.com)
  • In addition to the randomized Phase II clinical trial in frontline MDS, the Company is also preparing for the initiation of two open-label Phase II trials of Pracinostat: one in combination with Vidaza in frontline acute myeloid leukemia (AML) in the fall of 2013 and the other in combination with Vidaza or Dacogen^® (decitabine) in patients with refractory MDS soon thereafter. (biomedreports.com)
  • The primary objective of this phase 1 study was to evaluate the safety and tolerability of the anti-glucose regulated protein 78 monoclonal immunoglobulin M antibody PAT-SM6 in subjects with relapsed or refractory multiple myeloma. (haematologica.org)
  • In summary, single-agent PAT-SM6 was well tolerated with modest clinical activity in relapsed or refractory multiple myeloma. (haematologica.org)
  • For patients with relapsed or refractory multiple myeloma, response rates (RR) of 45% to 55% have been reported with the thalidomide/dexamethasone combination which compares favorably with the 25% to 35% RR of thalidomide alone ( 1 - 3 ). (aacrjournals.org)
  • High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. (springer.com)
  • Dr. Fox continued, "I am encouraged that all patients who completed the 48-week Phase 2 trial entered the extension phase of the study and look forward to updates from the Phase 2 extension, as well as to topline data from the Phase 3 trials evaluating ublituximab later this year. (globenewswire.com)
  • ULTIMATE I and ULTIMATE II are two independent Phase 3 trials. (globenewswire.com)
  • The Phase 3 trials, entitled ULTIMATE I and ULTIMATE II, are being conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) and are being led by Lawrence Steinman, MD, of Stanford University. (yahoo.com)
  • Funding obtained in this financing will advance multiple programs addressing ALI and HIE, including lead candidate RLS-0071, into Phase 2 clinical trials. (biospace.com)
  • INTERPRETATION AND CONCLUSIONS: In multiple myeloma a plateau phase of at least 6 months' duration has a higher impact on survival than the degree of response to conventional chemotherapy so plateau duration could be used as target of therapeutic trials. (haematologica.org)
  • If the excellent results from the phase II trials are reproduced, patients will have a new treatment option that has the potential to be much more efficacious than any other existing treatment. (btgplc.com)
  • A board to discuss future MS therapies in early stage (Phase I or II) trials. (thisisms.com)
  • Approximately 250 healthy volunteers and patients were treated with verdiperstat in Phase 1 and Phase 2 clinical trials. (rttnews.com)
  • The triple-DAA combination is currently being studied in Phase III clinical trials. (prnewswire.co.uk)
  • Our Phase III trials are progressing well and we remain focused on bringing an interferon-free treatment option to patients with HCV genotype 1 infection. (prnewswire.co.uk)
  • Very few patients accumulated disability at the rate expected from previous clinical trials, including our Phase 2 experience. (btgplc.com)
  • 1 , 2 At present, novel candidates, including elotuzumab (anti-CS-1), daratumumab (anti-CD38) and lucatumumab (anti-CD40), are being explored in phase 1-3 trials, with promising results in phase 1/2 trials, although their success remains to be established. (haematologica.org)
  • The first Phase III study in front line multiple myeloma was announced in July and is expected to start towards the end of this year. (globenewswire.com)
  • This new study of daratumumab in front line multiple myeloma is part of the extensive development plan created under our collaboration with Janssen Biotech for our CD38 antibody daratumumab," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. (globenewswire.com)
  • This Phase 1 trial is a randomized, placebo-controlled, multiple-ascending dose study of oral ACH-5228 administered to healthy volunteers outside the United States. (tmcnet.com)
  • The two-year randomized, double-blind, placebo-controlled Phase II clinical trial included 297 patients with relapsing MS. In the second year of the study, all patients were on drug. (drugs.com)
  • The Phase I single ascending dose, double blind placebo controlled randomized study will involve 56 healthy male volunteers who will receive the drug in eight escalating dose cohorts. (bio-medicine.org)
  • The results, detailed in an abstract titled GENESIS - A Phase III Randomized Double-Blind, Placebo-Controlled Trial, Evaluating Safety and Efficacy of BL-8040 and G-CSF in Mobilization of HSCs for Autologous Transplantation in Multiple Myeloma were presented in an oral presentation at the 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2019), today, March 27, 2019, in Frankfurt, Germany. (pharmiweb.com)
  • The GENESIS study is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of BL-8040 in combination with G-CSF, compared to placebo and G-CSF, for the mobilization of CD34 HSCs for autologous transplantation in multiple myeloma patients. (pharmiweb.com)
  • These response rates are numerically higher than the response rates seen after the first single injection in the double-blind placebo controlled Phase 3 studies. (empr.com)
  • In this phase 2, randomized, double-blind, placebo-controlled study, 124 patients with moderate-to-severe AD applied topical corticosteroids (TCSs) for 4 weeks before randomization to once-daily placebo, 2 mg of baricitinib, or 4 mg of baricitinib for 16 weeks. (em-consulte.com)
  • In the U.S., approximately 70,000 people are living with multiple myeloma and approximately 24,000 new cases are diagnosed annually. (fiercepharma.com)
  • 1] Worldwide, nearly 230,000 people are living with multiple myeloma and approximately 114,000 new cases are diagnosed annually. (fiercepharma.com)
  • 2] In Europe, approximately 89,000 people are living with multiple myeloma, and approximately 39,000 new cases are diagnosed annually. (fiercepharma.com)
  • Melflufen (INN melphalan flufenamide) is in development as a new treatment for the hematological malignancy multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. (prnewswire.com)
  • On 16 June 2019 , interim data from Oncopeptides' ongoing, pivotal Phase 2 HORIZON trial will also be presented as an oral presentation by Professor Paul G. Richardson , Professor of Medicine at Harvard Medical School and Clinical Program Leader, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute in Boston, Massachusetts , USA. (biospace.com)
  • In addition to the phase 3 trial, I-Mab is conducting a pivotal phase 2 study (NCT03860038) to evaluate the efficacy and safety of MOR202/TJ202 in combination with dexamethasone in subjects with r/r MM who received at least 2 prior lines of treatment. (pharmiweb.com)
  • The trial was initiated based on results from the Phase 1/2 CHAMPION study, which were presented (abstract no. 8527) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday, May 31 at 8 a.m. (prnewswire.com)
  • Additionally, Phase III results in people with relapsing MS (OPERA I and OPERA II studies) will be presented at ECTRIMS by Stephen Hauser, M.D., Chair of the Scientific Steering Committee of the OPERA studies and Chair of the Department of Neurology at the University of California San Francisco School of Medicine, on Friday, 9th October (Abstract #190, 14:40 - 14:52 CET). (roche.com)
  • This Phase III study is a randomized, open-label, multicenter study and will include approximately 700 newly diagnosed, chemotherapy naïve multiple myeloma patients ineligible for stem cell transplantation (SCT). (globenewswire.com)
  • Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP). (cun.es)
  • Single versus double autologous stem-cell transplantation for multiple myeloma. (springer.com)
  • Bortezomib-dezamethasone is superior to vincristine-doxorubicine-dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (springer.com)
  • The primary objective of the study is to demonstrate the superiority of a single dose of BL-8040 in combination with G-CSF, over placebo and G-CSF, in the mobilization of ≥ 6x10 6 CD34 cells/kg in up to 2 apheresis sessions, in preparation for autologous stem cell transplantation in multiple myeloma patients. (pharmiweb.com)
  • On August 24, positive topline results were announced from the phase III ALCYONE study of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) vs VMP alone as front-line treatment for newly diagnosed patients who are not considered candidates for autologous stem cell transplantation. (ascopost.com)
  • The phase III ALCYONE study is a randomized, open-label, multicenter study that includes 706 newly diagnosed patients with multiple myeloma who are ineligible for autologous stem cell transplantation. (ascopost.com)
  • Multiple myeloma (MM) remains largely incurable despite high-dose chemotherapy with autologous stem cell transplantation and novel treatments with different immunomodulatory drugs and proteasome inhibitors. (haematologica.org)
  • 6x10(6 )CD34 cells/kg in up to 2 apheresis sessions, in preparation for autologous stem cell transplantation in multiple myeloma patients. (epicos.com)
  • Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Scler. (bio-medicine.org)
  • MSD announced the results of their Phase III study of vorinostat at the 53rd Annual Meeting of the American Society of Hematology. (fdanews.com)
  • The results from the CHAMPION Phase 1/2 study form the basis of the Phase 3 ARROW study with the goal of potentially providing patients and physicians greater convenience with a once-weekly dosing schedule of Kyprolis,' said Sean E. Harper , M.D., executive vice president of Research and Development at Amgen. (prnewswire.com)
  • With our Phase 3 ULTIMATE program fully enrolled, we are looking forward to the results next year. (yahoo.com)
  • ROCKVILLE, Md.--(BUSINESS WIRE)--Jun 9, 2010 - Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. (drugs.com)
  • These data provide additional insight into the positive efficacy and safety results from our Phase 3 studies, showing there is a consistent beneficial effect with dimethyl fumarate in reducing MS relapses, brain lesions and disability," said Alfred Sandrock, M.D., Ph.D., senior vice president, Development Sciences and chief medical officer of Biogen Idec. (thestreet.com)
  • As a physician who treats patients with MS, the strong results observed in the Phase 3 studies of dimethyl fumarate indicate that it may provide an attractive combination of efficacy, safety and tolerability. (thestreet.com)
  • Interim results from the Phase 2 trial indicated that alemtuzumab-treated patients experienced a statistically significant reduction compared with Rebif-treated patients in the risk for sustained accumulation of disability and the risk for relapse for 24 months. (btgplc.com)
  • M illennium Pharmaceuticals, Inc, recently announced the presentation of results from three phase III investigations of bortezomib used in various combinations, for initial treatment of patients with multiple myeloma. (cancernetwork.com)
  • Results from a previous Phase 2 trial in MSA completed by AstraZeneca AB showed evidence of target engagement and favorable trends over 12 weeks on the Unified MSA Rating Scale, an exploratory clinical outcome measure. (rttnews.com)
  • AMSTERDAM , April 23, 2013 /PRNewswire/ -- (NYSE: ABBV) - Results from 'Aviator,' AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types. (prnewswire.co.uk)
  • Results so far show that mobilizing HSCs with a single BL-8040 dose combined with G-CSF is highly effective compared to using G-CSF alone, which typically requires up to 8 injections and multiple apheresis days. (pharmiweb.com)
  • THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Dec. 6, 2014 /PRNewswire/ -- Amgen (AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced today results of the Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial, which evaluated Kyprolis® (carfilzomib) for Injection plus Revlimid® (lenalidomide) and dexamethasone (KRd) compared with Revlimid and dexamethasone (Rd) in patients with relapsed multiple myeloma. (fiercepharma.com)
  • Delivering new potential treatment options exemplifies Onyx and Amgen's commitment to advancing the care of patients with multiple myeloma,' said Pablo J. Cagnoni, M.D., president, Onyx Pharmaceuticals, Inc. 'The results from the Phase 3 ASPIRE study bring us one step closer to establishing Kyprolis as a backbone of therapy in the treatment of multiple myeloma. (fiercepharma.com)
  • While it is unfortunate that the FOCUS study did not meet its primary endpoint of overall survival, we believe the results from the recent positive ASPIRE Phase 3 clinical trial will be sufficient to support regulatory submissions around the world,' said Pablo J. Cagnoni, M.D., president, Onyx Pharmaceuticals, Inc. (fiercepharma.com)
  • Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. (fiercepharma.com)
  • The interim results of the ALCYONE study yet again illustrate the potential of daratumumab in multiple myeloma in combination with existing treatment regimens, this time with VMP in the front-line setting. (ascopost.com)
  • San Francisco, CA, December 7, 2014 and Osaka, Japan, December 8, 2014 - Takeda Pharmaceutical Company Limited (TSE:4502) today announced results from an open-label, Phase 2 study evaluating the safety and efficacy of oral, single-agent ixazomib (MLN9708) as maintenance therapy in patients with multiple myeloma (MM) who had received ixazomib, lenalidomide and dexamethasone as induction therapy. (takeda.com)
  • October 29, 2018 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today topline results from the Phase III MAIA study (MMY3008) of daratumumab in combination with lenalidomide and dexamethasone (DRd) versus Rd alone as treatment for newly diagnosed patients who are not candidates for high dose chemotherapy and autologous stem cell transplant (ASCT). (apnews.com)
  • Full results from the phase III SUNBEAM™ and RADIANCE™ Part B studies evaluating two doses of oral ozanimod compared with Avonex® (interferon beta-1a) (IFN) in people with RMS will be presented as an oral and a late-breaking oral presentation, respectively. (ntbinfo.no)
  • New drugs in multiple myeloma - role of carfilzomib and pomalidomide. (yahoo.com)
  • The international, randomized Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial evaluated Kyprolis in combination with lenalidomide and low-dose dexamethasone, versus lenalidomide and low-dose dexamethasone alone, in patients with relapsed multiple myeloma following treatment with one to three prior regimens. (fiercepharma.com)
  • On July 20, 2012, the FDA granted accelerated approval of Kyprolis® (carfilzomib) for Injection for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy. (fiercepharma.com)
  • The multicenter Phase II trial is expected to enroll 100 patients with a one-to-one randomization. (biomedreports.com)
  • Johnson & Johnson unit Janssen Research & Development LLC's phase 3 studies showed that Darzalex in combination with bortezomib and dexamethasone, or lenalidomide and dexamethasone, improved progression-free survival and the overall response rate for previously treated patients with multiple myeloma, regardless of cytogenetic risk. (spglobal.com)
  • Fifty patients were enrolled in the Phase 2 cohort and received ixazomib, lenalidomide and dexamethasone as induction therapy for up to twelve 28-day cycles. (takeda.com)
  • In the last eighteen months, GW has put in place a substantial Phase III clinical programme for global regulatory success for Sativex in multiple indications. (rutgers.edu)
  • The additional capital raised will support the advancement of our lead candidate, RLS-0071, into Phase 2 programs for multiple indications," said Ulrich Thienel, M.D., Ph.D., ReAlta's Chief Executive Officer. (biospace.com)
  • Vorinostat, designed for treatment in patients with progressive multiple myeloma, has met its primary endpoint in a Phase III study for investigational use in combination with bortezomib. (fdanews.com)
  • To compare the safety of minocycline vs. placebo in patients receiving induction therapy for multiple myeloma with a regimen containing thalidomide, and/or bortezomib 2. (mdanderson.org)
  • To compare the effect of minocycline vs. placebo on peripheral nerve function, as determined by a change in touch detection threshold, among patients receiving induction therapy of previously untreated multiple myeloma with a regimen containing thalidomide, and/or bortezomib. (mdanderson.org)
  • To evaluate the effect of minocycline vs. placebo on patients' neuropathic symptoms during induction therapy of previously untreated multiple myeloma with a regimen containing thalidomide and/or bortezomib. (mdanderson.org)
  • The use of newer therapeutic agents such as thalidomide, lenalidomide and bortezomib has markedly increased the median overall survival of multiple myeloma (MM) patients during the past decade. (nature.com)
  • ANCHOR is a phase 1/2 trial where melflufen and dexamethasone is dosed in combination with either bortezomib or daratumumab. (biospace.com)
  • The primary objective of the phase 1 part of the study is to determine the optimal dose of melflufen, up to a maximum of 40 mg, and dexamethasone in combination with bortezomib or daratumumab. (biospace.com)
  • This phase 1/2 trial in 60 untreated MM patients aged at least 65 years (half older than 75 years) was designed to determine dosing, safety, and efficacy of bortezomib plus MP (VMP). (cun.es)
  • Genmab A/S (OMX: GEN) announced today that its collaboration partner, Janssen Biotech, Inc. ("Janssen") plans to start a new Phase III study of daratumumab in multiple myeloma. (globenewswire.com)
  • Today's news is the fourth daratumumab Phase III study to be announced. (globenewswire.com)
  • Daratumumab is in clinical development for multiple myeloma (MM). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. (globenewswire.com)
  • We are very pleased with the outcome of the preplanned interim analysis in this study, which adds further to our hope that daratumumab could potentially become the critical driver redefining combination treatment in multiple myeloma," said Jan van de Winkel, PhD, Chief Executive Officer of Genmab. (ascopost.com)
  • We are highly encouraged by this data as this is the fifth randomized study showing a profound benefit when adding daratumumab to standard of care treatments in multiple myeloma, and the second showing efficacy for patients with newly diagnosed multiple myeloma who are not eligible for ASCT. (apnews.com)
  • The objective of this multicenter, open-label, Phase 1 dose-escalation study is the characterization of safety and tolerability of CLR 131 administered either as a single-dose or split-dose, 30-minute infusion(s) in patients with R/R MM. In Cohorts 1-4, patients received doses of 12.5 mCi/m 2 up to 31.25 mCi/m 2 . (yahoo.com)
  • The Phase 1 multicenter, open-label, dose-escalation study is designed to evaluate the safety and tolerability of CLR 131 administered as a 30-minute IV infusion, either as a single bolus dose or as two fractionated doses, in patients with R/R MM. All doses to date have been deemed safe and well tolerated by an independent Data Monitoring Committee (DMC). (benzinga.com)
  • In addition to the ongoing Phase 1 dose-escalation study and the Phase 2 (CLOVER-1) trial, the company recently initiated a Phase 1 open-label, dose-escalating study in pediatric solid tumors and lymphoma to evaluate the safety and tolerability of a single intravenous administration of CLR 131 in up to 30 children and adolescents with cancers including neuroblastoma, sarcomas, lymphomas (including Hodgkin's lymphoma) and malignant brain tumors. (benzinga.com)
  • The presentation showed that this Phase 1 Study met its primary objective, which was to evaluate the safety profile and determine the maximum tolerated dose (MTD) of a single IV dose of RTL1000. (bio-medicine.org)
  • Objective To independently evaluate the impact of the second phase of the Health Foundation's Safer Patients Initiative (SPI2) on a range of patient safety measures. (bmj.com)
  • The primary objective of the Phase 1 portion of the study was to determine the MTD of once-weekly Kyprolis with dexamethasone. (prnewswire.com)
  • The primary objective of the Phase 2 portion of the study was to determine the ORR. (prnewswire.com)
  • To determine the Time to best response Phase 2: Primary objective: 1. (mdanderson.org)
  • Additional patients per regimen are recruited in the phase 2 part of the trial where the primary objective is ORR. (biospace.com)
  • BACKGROUND AND OBJECTIVE: In multiple myeloma (MM) patients treated with conventional chemotherapy, the attainment and duration of a plateau phase seems to affect survival more than the degree of response to initial treatment. (haematologica.org)
  • The objective of this phase 2b study was to assess the safety, and efficacy of ABT-450/r (dosed 100/100 to 200/100mg once daily), ABT-267 (25mg once daily), ABT-333 (400mg twice daily) and ribavirin in non-cirrhotic treatment-naive patients and prior peg-interferon/ribavirin null responders administered for 8, 12 or 24 weeks. (prnewswire.co.uk)
  • The primary objective of the Phase 2 component of the study was the percent of patients achieving a very good partial response [VGPR] or better (defined as complete response [CR] + VGPR). (takeda.com)
  • This open-label Phase I study aims at assessing the safety and clinical activity of the NKR-2 treatment administered 3 times with a 2-week interval between each administration in different tumor types. (centerwatch.com)
  • Investigators will enroll between 22 to 28 patients in the prospective, multi-center, open-label, single-arm Phase 1/2 study. (lls.org)
  • Auxilium Pharmaceuticals announced positive top-line data from its open-label phase 3b trial evaluating Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. (empr.com)
  • This phase 3b study was an open-label study that was designed to assess the safety and efficacy of concurrent administration of two injections of Xiaflex into the same hand of subjects with at least two Dupuytren's contractures caused by palpable cords. (empr.com)
  • About the MAIA (MMY3008) studyThe Phase III study (NCT02252172) is a randomized, open-label, multicenter study that includes 737 newly diagnosed patients with multiple myeloma who are not candidates for high dose chemotherapy and ASCT. (apnews.com)
  • Methods Forty consecutive patients with moderate to severe DED were included in a phase IIa, prospective, open label, multiple-dose, clinical trial to receive rhNGF eye drops at 20 µg/mL (Group 1: G1) or at 4 µg/mL (Group 2: G2) concentrations, two times a day in both eyes for 28 days ( NCT02101281 ). (bmj.com)
  • A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. (biomedsearch.com)
  • 1 . A pharmaceutical composition comprising a matrix capable of delivering at least one therapeutic agent to a bodily compartment under controlled release conditions, said matrix comprising a homogeneous mixture of aqueous phase and at least one other phase, at least one therapeutic agent present in at least one of said phases, and at least one cross-linked polymer physically entrapping said at least one therapeutic agent. (google.com.au)
  • Anti-CD20 therapy has quickly become a very important treatment option for patients with MS, and we believe our Phase 2 data highlight the potential therapeutic benefits for ublituximab delivered in a convenient one-hour infusion following day 1. (globenewswire.com)
  • CLR 131 is the company's lead therapeutic PDC product candidate and is currently being evaluated in both Phase 2 and Phase 1 clinical studies. (benzinga.com)
  • These data suggest that as an oral proteasome inhibitor, ixazomib may be an important new agent for further clinical investigation in the maintenance therapy of multiple myeloma," said Michael Vasconcelles, M.D., Head, Oncology Therapeutic Area Unit, Takeda. (takeda.com)
  • In support of the postulate that hematologic malignancies are possible targets for COX-2 inhibitors, COX-2 overexpression has been shown in various leukemia, B-cell lymphoma, and multiple myeloma cell lines ( 15 , 22 - 25 ). (aacrjournals.org)
  • The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. (springer.com)
  • Patients with a diagnosis of symptomatic multiple myeloma or a clinical suspicion of an ongoing progression into symptomatic multiple myeloma. (knowcancer.com)
  • Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. (springer.com)
  • Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody, TG-1501, as well as its covalently-bound Bruton's Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801, into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. (yahoo.com)
  • In November 2009, HGS and Aegera Therapeutics announced the initiation of a Phase 1 trial of HGS' lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors. (drugs.com)
  • PTK/ZK is a multiple VEGF receptor inhibitor that blocks the activity of all known VEGF receptor tyrosine kinases. (nih.gov)
  • Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma. (springer.com)
  • Patients in the study had previously untreated multiple myeloma and were ineligible for stem cell transplantation. (cancernetwork.com)
  • HGS1029 as monotherapy is also being studied in an ongoing Phase 1 study initiated in 2008 in patients with advanced solid tumors. (drugs.com)
  • In addition, interim safety data from a Phase 3 extension study indicate that continued exposure to dimethyl fumarate did not result in any new or worsening safety signals, and that its safety and tolerability profiles were consistent with previous studies. (thestreet.com)
  • The majority of patients received intermittent cycles of chemotherapy (melphalan or interferon) during the plateau phase. (haematologica.org)
  • In addition, similar high SVR rates observed after 12 and 24 weeks of treatment in the Phase IIb trial reinforce the adequacy of the 12-week treatment duration for the investigational interferon-free, triple DAA combination. (prnewswire.co.uk)
  • MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve- insulating myelin. (bio-medicine.org)
  • The successful completion of this Phase 1 study represents a major milestone in the potential treatment of this devastating disease and in the development of our proprietary platform technology," said Dr. Al Ferro, President and CEO of Artielle ImmunoTherapeutics, Inc. "We plan to move aggressively to bring these novel, first-in-class products to the market place. (bio-medicine.org)
  • A total of five patients died during the study, all of which were in the Phase 2 portion of the study: one patient each had cause of death reported as cardiopulmonary arrest, pneumonia, disease progression, acute respiratory distress syndrome and acute kidney injury. (prnewswire.com)
  • Alzforum first reported on this data from the Phase Transitions in Biology and Disease meeting in Leuven last May ( May 2017 conference news ). (alzforum.org)
  • And finally, to add texture to it all, researchers led by Amy Gladfelter, University of North Carolina, Chapel Hill, report in the same issue that the shape of RNA determines the content, biophysical properties, and phase separation of RNA-protein assemblies, proving that there is much more to know about these particles and their regulation in health and disease. (alzforum.org)
  • Highest values were stated in active phases of the disease (at presentation and in progression). (hindawi.com)
  • The FDA granted orphan drug designation for CLR 131 for the treatment of multiple myeloma as well as orphan drug and rare pediatric disease designations for CLR 131 for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. (benzinga.com)
  • Researchers designed a randomized phase II clinical trial study including 21 MS patients (average age of 36) whose disability due to the disease had worsened in the previous year despite the fact that the patients were under conventional medication treatment. (cancerconnect.com)
  • Nearly all patients with multiple myeloma experience a relapse following treatment, underscoring the need for new options that not only extend the time patients live without their disease progressing, but also improve the depth and duration of a response to treatment,' said Dr. Stewart. (fiercepharma.com)
  • The loss of brain parenchymal volume underlies the progressive accumulation of physical disability from the initial phase of the disease, which becomes more demonstrable only if studied with longer observation periods. (bmj.com)
  • This course is split into two parts (Part a and b) and forms part of Phase 2 of the Musculoskeletal Remedial and Exercise Therapy course. (eventbrite.co.uk)
  • Enter Artielle ImmunoTherapeutics, a Portland biotech company that will launch an FDA phase-two clinical trial this year for a new therapy researchers say appears to also reverse the dysregulation of the immune system associated with MS and promotes nerve regeneration. (oregonbio.org)
  • ReAlta is currently conducting a Phase 1 trial in healthy volunteers for RLS-0071, as well as a separate proof of concept study to evaluate RLS-0071 as a therapy for ALI in hospitalized COVID-19 subjects. (biospace.com)
  • Johnson & Johnson's Janssen unit is another company trying to target BCMA - its CAR-T therapy JNJ-68284528 which works on the receptor was granted Breakthrough Therapy status in multiple myeloma by the FDA earlier this month. (pharmaphorum.com)
  • The 682-patient, randomized, phase III VISTA trial (Velcade as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone). (cancernetwork.com)
  • NEW HAVEN, Conn., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced dosing of the first healthy volunteer in a Phase 1 multiple ascending dose (MAD) study of ACH-5228, one of the company's next-generation oral, small-molecule factor D inhibitors. (tmcnet.com)
  • The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or. (google.com.au)
  • 3 . The pharmaceutical composition of claim 2 wherein said oil phase and said aqueous phase are in the form of an emulsion. (google.com.au)
  • In this study, we shed light on the initial addition of hydroxyl radicals (HO˙) to multiple carboxylated and hydroxylated benzene compounds in aqueous-phase advanced oxidation processes (AOPs). (rsc.org)
  • The ab initio DFT method was first used to find and optimize aqueous-phase transition state structures, then the TD-DFT was used to analyze molecular orbitals (MOs) of the optimized transition state structures to reveal the functional groups that are responsible for the individual absorption peaks. (rsc.org)
  • These investigations into the experimental transient spectra coupled with the theoretical analysis using the TD-DFT enable us to visualize an initial transformation of organic compounds induced by the aqueous phase HO˙ oxidation. (rsc.org)
  • Moreover, the experimental reaction rate constants and the theoretically calculated aqueous phase free energies of activation provide quantitative insights into the addition of HO˙ to multiple carboxylated and hydroxylated benzene compounds. (rsc.org)
  • Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and the immunomodulatory agent thalidomide (Thal) has proven effectiveness in active MM. We hypothesized that treatment with Thal and ZLD would prolong the time to progression (TTP) to MM over ZLD alone. (biomedsearch.com)
  • The vast majority of primary human cutaneous melanomas undergo a slow and gradual progression from a clinically indolent, curable radial growth phase (RGP) to a malignant vertical growth phase. (aacrjournals.org)
  • The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). (clinicaltrials.gov)
  • We have two further Phase III neuropathic pain studies due to report later this year and we need to consider with our marketing partners the relative benefits of awaiting that data before submitting the next regulatory filing. (rutgers.edu)
  • Further, these Phase 2 data strengthen our confidence in the design of our fully enrolled Phase 3 ULTIMATE program for ublituximab in RMS, for which we are targeting topline data in the second half of this year. (globenewswire.com)
  • Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer stated, "We are extremely pleased by the final Phase 2 MS data presented last night at ACTRIMS. (yahoo.com)
  • We believe our Phase 2 data present a compelling profile of best-in-class activity coupled with a convenient one-hour infusion. (yahoo.com)
  • These data support the ongoing, fully enrolled, international Phase 3 program evaluating ublituximab for the treatment of RMS. (yahoo.com)
  • Statements included in this press release, particularly those with respect to anticipating the benefit of the data seen in the Phase 2 MS trial program and performance in of ublituximab in the Phase 3 ULTIMATE clinical program may be forward-looking statements that involve a number of risks and uncertainties. (yahoo.com)
  • We analyzed 25 SNPs, 21 of which not previously studied, and gene expression data from six phase I metabolic genes, including cytochrome P450s, microsomal epoxide hydrolase, and myeloperoxidase. (aacrjournals.org)
  • One of the important properties of this code is that the cross correlation at data segment is always zero, which means that phase intensity-induced noise (PIIN) is reduced. (spiedigitallibrary.org)
  • MEI Pharma, Inc. (Nasdaq: MEIP) , an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patients have been dosed in a Phase II clinical trial of its lead drug candidate Pracinostat in combination with Vidaza (azacitidine) in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). (biomedreports.com)
  • The initiation of this randomized Phase II trial is an important milestone in the clinical development of Pracinostat," said Robert D. Mass, MD, Chief Medical Officer of MEI Pharma. (biomedreports.com)